To use all functions of this page, please activate cookies in your browser.
My watch list
my.bionity.com
my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
20 Current news of Astellas
rss
Astellas and UCB announce approval of Cimzia in Japan for the treatment of rheumatoid arthritis
04-01-2013
Astellas Pharma Inc. and UCB S.A. announced that UCB Japan has received marketing approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) for Cimzia® (certolizumab pegol). Cimzia®, under joint development in Japan, has been approved as a 200 mg syringe for subcutaneous ...
Abbott to Collaborate with Astellas in CMV Vaccine Trial
10-09-2012
Abbott announced that it has signed an agreement to collaborate with Astellas Pharma Global Development in a Phase 3 clinical trial for ASP0113 (TransVax™), an investigational vaccine licensed from Vical Incorporated for preventing cytomegalovirus (CMV) reactivation in transplant ...
MediGene Completes the Transfer of Eligard Rights for EU Countries to Astellas
04-03-2011
MediGene AG announced that exclusive European rights to the cancer drug Eligard® have been transferred to Astellas Pharma Europe Ltd., with effect from March 1, 2011. This will trigger a second milestone payment from Astellas to MediGene, amounting to EUR 15 million, as agreed in the July ...
Basilea and Astellas update isavuconazole phase III trial in consultation with FDA
29-11-2010
Basilea Pharmaceutica Ltd. announced that in consultation with the U.S. Food and Drug Administration (FDA) Basilea and its partner Astellas Pharma Inc. have agreed to use 'all-cause mortality' as the primary endpoint of the phase III clinical study investigating isavuconazole for the ...
MediGene sells full European rights for Eligard® to Astellas for EUR 25 million and ongoing royalties
21-07-2010
MediGene AG announces the sale of full European marketing and distribution rights to Eligard® (leuprolide acetate, for the treatment of hormone-dependent prostate cancer) to Astellas Pharma Europe Ltd., previously MediGene's European marketing partner for Eligard®. MediGene acquired these ...
Astellas Pharma Canada Appoints New President
01-07-2010
Astellas Pharma Canada, Inc. announced that Michael Tremblay has been appointed president of the Canadian subsidiary of Astellas Pharma Inc. His predecessor, Fumiaki Sakurai, will return to Japan to assume a new role in the company's Asia International Division. Mr. Tremblay has almost 35 ...
Basilea provides update on phase III program for the antifungal isavuconazole
29-06-2010
Basilea Pharmaceutica Ltd. announced that its partner Astellas Pharma Inc.has initiated the formal process to allow continuation of patient recruitment into the phase III clinical studies of isavuconazole for the treatment of life-threatening invasive fungal infections. Certain study protocol ...
Basilea announces global partnership with Astellas for its antifungal isavuconazole
26-02-2010
Basilea announced that Basilea Pharmaceutica International Ltd. has entered into a license, co-development and co-promotion agreement with Astellas Pharma Inc. for Basilea's azole antifungal agent isavuconazole in phase III clinical development for the treatment of life-threatening invasive ...
Cardiome And Astellas Announce Receipt Of FDA Approvable Letter For KYNAPID(TM)
13-08-2008
Cardiome Pharma Corp. and its co-development partner Astellas Pharma US, Inc. ("Astellas") today announced that they have received an action letter dated August 8, 2008 from the U.S. Food and Drug Administration (FDA) for KYNAPID(TM) (vernakalant hydrochloride) Injection for the treatment of ...
MorphoSys and Astellas Extend Alliance for Use of HuCAL GOLD to Develop Novel Antibody Therapies
26-02-2008
MorphoSys AG announced that Astellas Pharma Inc. has decided to extend the current collaboration between the two companies. The collaboration, originally signed in March 2007, will now run its full term. Under the agreement, which is now extended for four more years until March 2012, Astellas ...
Netmeeting
